SOCIAL CAPITAL

PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on:

화요일, 2월 15, 2022

Health, Technology, Other Technology, Other Health, General Health, Clinical Trials, Biotechnology, Adoption, LSE, Prospectus, XV, Private Securities Litigation Reform Act, Therapy, Technology, Suite, U.S. Securities and Exchange Commission, Government budget balance, Acquisition, U.S. FDA, Entrepreneurship, COVID-19, PALO, Mergers and acquisitions, Company, PRTC, Tripura Merger Agreement, SEC, Xi, Registration statement, Securities Act of 1933, Vii, SCS, Twitter, Degenerative disease, Sale, Research, 100,000, Industry, Connection, Social capital, ALL, Risk, Brain, Capitalism, Nasdaq, THE, Register, PureTech Health, Name, Cancer, Communication, Medicine, Form, Business architecture, Forward-looking statement, Annual report, Environment, Proxy, Biology, FDA, Axis, Failure, BIG, Online gambling, Audit, Security (finance), Property management, Risk management, Yolo Akili, Akili, Social Capital, Social Capital Suvretta Holdings Corp I, PureTech Health, AKILI, SOCIAL CAPITAL, SOCIAL CAPITAL SUVRETTA HOLDINGS CORP I, PURETECH HEALTH

The full text of the announcement from Akili is as follows:

Key Points:

The full text of the announcement from Akili is as follows:
Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp.
and PALO ALTO, Calif. February 14, 2022 Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, announced that Social Capital Suvretta Holdings Corp.
I (SCS) (Nasdaq: DNAA) has filed with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 (the Registration Statement), which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.
While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Akili and the proposed business combination with SCS.

Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on:

월요일, 2월 14, 2022

Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, announced that Social Capital Suvretta Holdings Corp.

Key Points:

Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, announced that Social Capital Suvretta Holdings Corp.
I (SCS) (Nasdaq: DNAA) has filed with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 (the Registration Statement), which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.
While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Akili and the proposed business combination with SCS.
Neither Akili nor SCS gives any assurance that either Akili or SCS, or the combined company, will achieve its expectations.

Perimeter Medical Imaging AI Announces Closing of Strategic Private Placement to Social Capital

Retrieved on:

목요일, 1월 27, 2022

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, is pleased to announce the closing of its previously announced private placement of units (each, a Unit) for gross proceeds of C$48.7 million to the Company (the Private Placement).

Key Points:

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, is pleased to announce the closing of its previously announced private placement of units (each, a Unit) for gross proceeds of C$48.7 million to the Company (the Private Placement).
The Private Placement included the C$43.4 million strategic investment in the Company (the Investment) by Social Capital.
Subject to the accelerated expiry clause described above, all Warrants will expire five years following the closing of the Private Placement.
About Perimeter Medical Imaging AI, Inc.
With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on:

수요일, 1월 26, 2022

Technology, Mobile, Wireless, Venture Capital, Other Technology, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Akili, Social Capital, Social Capital Suvretta Holdings Corp I, AKILI, SOCIAL CAPITAL, SOCIAL CAPITAL SUVRETTA HOLDINGS CORP I

Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp.

Key Points:

Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp.
This core platform has the potential to be applied across a diverse set of indications within psychiatry and neurology.
With its first-ever, clinically validated digital therapeutic (EndeavorRx), Akili has the unique opportunity to change how we treat pediatric ADHD.
Neither Akili nor SCS gives any assurance that either Akili or SCS, or the combined company, will achieve its expectations.

PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on:

수요일, 1월 26, 2022

Health, FDA, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Akili, Social Capital, Social Capital Suvretta Holdings Corp I, PureTech Health, AKILI, SOCIAL CAPITAL, SOCIAL CAPITAL SUVRETTA HOLDINGS CORP I, PURETECH HEALTH

The full text of the announcement from Akili is as follows:

Key Points:

The full text of the announcement from Akili is as follows:
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp.
Specifically, current treatment options are designed to focus on symptoms and coping strategies instead of directly targeting cognitive functioning.
These therapeutic shortfalls are especially concerning for younger populations who are potentially facing a lifetime of managing these conditions.
With its first-ever, clinically validated digital therapeutic (EndeavorRx), Akili has the unique opportunity to change how we treat pediatric ADHD.

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

Retrieved on:

화요일, 1월 18, 2022

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, ProKidney, Social Capital, Social Capital Suvretta Holdings Corp. III, PROKIDNEY, SOCIAL CAPITAL, SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III

ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (SCS) (Nasdaq: DNAC), a special purpose acquisition company.

Key Points:

ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (SCS) (Nasdaq: DNAC), a special purpose acquisition company.
If left untreated, many CKD patients progress to end-stage renal disease (ESRD) or kidney failure and require dialysis or kidney transplant.
The Phase 3 program,initiated in January 2022, may enroll up to 1,500 participants withprimary analysis projected to occur in 2025.
Neither ProKidney nor SCS gives any assurance that either ProKidney or SCS, or the combined company, will achieve its expectations.

Perimeter Medical Imaging AI Announces Strategic Private Placement to Social Capital

Retrieved on:

수요일, 12월 15, 2021

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that it has entered into a subscription agreement pursuant to which an affiliate of Social Capital Holdings Inc. (Social Capital) will make a strategic C$43.4 million investment in the Company.

Key Points:

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that it has entered into a subscription agreement pursuant to which an affiliate of Social Capital Holdings Inc. (Social Capital) will make a strategic C$43.4 million investment in the Company.
Chamath Palihapitiya, CEO of Social Capital, said, Perimeters advanced imaging technology has the opportunity to materially improve cancer surgery outcomes.
Social Capital will also enter into an investor rights agreement with Perimeter at the closing of the Private Placement, which will provide Social Capital with the right to nominate one director to the board of Perimeter, with anti-dilution rights to participate in future financings, and with customary registration rights.
About Perimeter Medical Imaging AI, Inc.
With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.